Cargando…

PSAT226 Management of a Patient with Primary Hyperparathyroidism by Discontinuation of Hydrochlorothiazide: Preventing the Need for Surgical Management

INTRODUCTION: Recurrent or persistent primary hyperparathyroidism has been reported in 2-5% of patients after the initial operation. Reoperations have been associated with significant complications. The aim of this presentation is to highlight the importance of medical management prior to proceeding...

Descripción completa

Detalles Bibliográficos
Autores principales: Romao, Isabela J, Shanik, Michael Howard, Velayati, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624928/
http://dx.doi.org/10.1210/jendso/bvac150.453
_version_ 1784822357867626496
author Romao, Isabela J
Shanik, Michael Howard
Velayati, Sara
author_facet Romao, Isabela J
Shanik, Michael Howard
Velayati, Sara
author_sort Romao, Isabela J
collection PubMed
description INTRODUCTION: Recurrent or persistent primary hyperparathyroidism has been reported in 2-5% of patients after the initial operation. Reoperations have been associated with significant complications. The aim of this presentation is to highlight the importance of medical management prior to proceeding to surgery. CASE PRESENTATION: A 72-year-old man with a past medical history of coronary artery disease and asthma was found to have hypercalcemia and osteoporosis and was diagnosed with primary hyperparathyroidism in 2009. He had no family history of hypercalcemia. Three parathyroid glands were removed in 2010 and his parathyroid hormone normalized immediately after the surgery. About 10 years after the surgery, he developed hypertension and calcium-type kidney stones. He was treated with losartan 50 mg daily and hydrochlorothiazide 12.5 mg daily. One year later his calcium level was 11.1 mg/dL, parathyroid hormone (PTH) 70 pg/mL, 25-OH vitamin D level 44 ng/mL and creatinine was 0.8 mg/dL. A CT scan demonstrated a lesion measuring 1.3×1.1×1.6 cm which was suspicious for an ectopic parathyroid adenoma in the left ascending aorta. He was scheduled for surgical exploration and removal of the parathyroid adenoma for recurrence of primary hyperparathyroidism. Prior to the surgery, the patient was evaluated in our office for a second opinion. Physical exam and review of systems were unremarkable. Thyroid ultrasound showed a heterogeneous thyroid with no thyroid nodules or parathyroid adenoma. Adequate hydration was recommended and since his blood pressure was well-controlled, hydrochlorothiazide was discontinued. Surgery was canceled to confirm that the hypercalcemia was due to hydrochlorothiazide rather than hyperparathyroidism. After 4 months of follow-up, his blood pressure remained controlled on monotherapy with Losartan, and the repeat calcium level was 9.6 mg/dL with a PTH level of 44 pg/mL. CONCLUSION: Post-surgical patients with a history of primary hyperparathyroidism, when presenting with hypercalcemia can get misdiagnosed as recurrent or persistent primary hyperparathyroidism; therefore, other causes of hypercalcemia including medications that may affect the calcium level and its metabolism should be considered and excluded prior to surgical management. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m.
format Online
Article
Text
id pubmed-9624928
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96249282022-11-14 PSAT226 Management of a Patient with Primary Hyperparathyroidism by Discontinuation of Hydrochlorothiazide: Preventing the Need for Surgical Management Romao, Isabela J Shanik, Michael Howard Velayati, Sara J Endocr Soc Bone & Mineral Metabolism INTRODUCTION: Recurrent or persistent primary hyperparathyroidism has been reported in 2-5% of patients after the initial operation. Reoperations have been associated with significant complications. The aim of this presentation is to highlight the importance of medical management prior to proceeding to surgery. CASE PRESENTATION: A 72-year-old man with a past medical history of coronary artery disease and asthma was found to have hypercalcemia and osteoporosis and was diagnosed with primary hyperparathyroidism in 2009. He had no family history of hypercalcemia. Three parathyroid glands were removed in 2010 and his parathyroid hormone normalized immediately after the surgery. About 10 years after the surgery, he developed hypertension and calcium-type kidney stones. He was treated with losartan 50 mg daily and hydrochlorothiazide 12.5 mg daily. One year later his calcium level was 11.1 mg/dL, parathyroid hormone (PTH) 70 pg/mL, 25-OH vitamin D level 44 ng/mL and creatinine was 0.8 mg/dL. A CT scan demonstrated a lesion measuring 1.3×1.1×1.6 cm which was suspicious for an ectopic parathyroid adenoma in the left ascending aorta. He was scheduled for surgical exploration and removal of the parathyroid adenoma for recurrence of primary hyperparathyroidism. Prior to the surgery, the patient was evaluated in our office for a second opinion. Physical exam and review of systems were unremarkable. Thyroid ultrasound showed a heterogeneous thyroid with no thyroid nodules or parathyroid adenoma. Adequate hydration was recommended and since his blood pressure was well-controlled, hydrochlorothiazide was discontinued. Surgery was canceled to confirm that the hypercalcemia was due to hydrochlorothiazide rather than hyperparathyroidism. After 4 months of follow-up, his blood pressure remained controlled on monotherapy with Losartan, and the repeat calcium level was 9.6 mg/dL with a PTH level of 44 pg/mL. CONCLUSION: Post-surgical patients with a history of primary hyperparathyroidism, when presenting with hypercalcemia can get misdiagnosed as recurrent or persistent primary hyperparathyroidism; therefore, other causes of hypercalcemia including medications that may affect the calcium level and its metabolism should be considered and excluded prior to surgical management. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m. Oxford University Press 2022-11-01 /pmc/articles/PMC9624928/ http://dx.doi.org/10.1210/jendso/bvac150.453 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Bone & Mineral Metabolism
Romao, Isabela J
Shanik, Michael Howard
Velayati, Sara
PSAT226 Management of a Patient with Primary Hyperparathyroidism by Discontinuation of Hydrochlorothiazide: Preventing the Need for Surgical Management
title PSAT226 Management of a Patient with Primary Hyperparathyroidism by Discontinuation of Hydrochlorothiazide: Preventing the Need for Surgical Management
title_full PSAT226 Management of a Patient with Primary Hyperparathyroidism by Discontinuation of Hydrochlorothiazide: Preventing the Need for Surgical Management
title_fullStr PSAT226 Management of a Patient with Primary Hyperparathyroidism by Discontinuation of Hydrochlorothiazide: Preventing the Need for Surgical Management
title_full_unstemmed PSAT226 Management of a Patient with Primary Hyperparathyroidism by Discontinuation of Hydrochlorothiazide: Preventing the Need for Surgical Management
title_short PSAT226 Management of a Patient with Primary Hyperparathyroidism by Discontinuation of Hydrochlorothiazide: Preventing the Need for Surgical Management
title_sort psat226 management of a patient with primary hyperparathyroidism by discontinuation of hydrochlorothiazide: preventing the need for surgical management
topic Bone & Mineral Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624928/
http://dx.doi.org/10.1210/jendso/bvac150.453
work_keys_str_mv AT romaoisabelaj psat226managementofapatientwithprimaryhyperparathyroidismbydiscontinuationofhydrochlorothiazidepreventingtheneedforsurgicalmanagement
AT shanikmichaelhoward psat226managementofapatientwithprimaryhyperparathyroidismbydiscontinuationofhydrochlorothiazidepreventingtheneedforsurgicalmanagement
AT velayatisara psat226managementofapatientwithprimaryhyperparathyroidismbydiscontinuationofhydrochlorothiazidepreventingtheneedforsurgicalmanagement